NCT01229254已完成2 期
A Phase II, Open-label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients With Nonvalvular Atrial Fibrillation or Atrial Flutter
Portola Pharmaceuticals0 个研究点目标入组 189 人开始时间: 2010年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 189
- 主要终点
- Steady-state C12 hr on Days 14, 18, and 21 After Weight-based Dosing
研究概览
简要总结
The primary purpose of this study is to optimize drug exposure in the target population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •In the opinion of the investigator, participant requires long term anticoagulation for stroke prevention in atrial flutter (AF).
- •Men and women ≥18 years of age.
- •Participant has current non-valvular atrial fibrillation (NVAF) or AF or electrocardiogram (ECG) or Holter documentation within past 12 months.
- •Participant has an international normalized ratio (INR) ≤ 2.2 at allocation (Visit 2).
- •A participant who is of reproductive potential agrees to remain abstinent or use (or have their partner use) 2 acceptable methods of birth control for the duration of the study. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, condom, vasectomy, and hormonal contraception.
- •Participant understands the study procedures and risks involved with the study, and voluntarily agree to participate by giving written informed consent.
排除标准
- •Participant is currently participating in another drug study or has received an investigational drug within 30 days prior to enrollment.
- •Participant is a woman who is pregnant, lactating or of child-bearing potential who refuses to use a medically acceptable form of contraception throughout the study.
- •Participant has a body weight less than 40 kg (88 lbs) or greater than 200 kg (440 lbs).
- •Participant routinely consumes more than 2 alcoholic drinks per day (average >14 alcoholic drinks per week) or greater than 5 drinks within 2 hours on occasion.
- •Prohibited Medical Conditions
- •Participant has any condition or situation which, in the opinion of the investigator, might pose a risk to the participant or interfere with participation in the study.
- •Conditions associated with an increased risk of bleeding Active bleeding.
- •Conditions other than AF that require chronic anticoagulation.
- •Severe aortic and mitral valvular disease requiring surgical intervention.
- •Previous known history of coagulopathy (e.g.: Factor V Leiden, Protein C Deficiency, Protein S Deficiency, Antiphospholipid Syndrome, etc.).
- •Active infective endocarditis.
- •Participant has history of familial long QT interval (the QT interval is the portion of an electrocardiogram (ECG) between the onset of the Q wave and the end of the T wave, representing the total time for ventricular depolarization and repolarization) syndrome or prolonged Bazett-corrected QT interval (QTcB) (males > 470 msec; females >480 msec) at baseline as measured on a 12-lead ECG.
- •Participant has serious pulmonary, hepatic, metabolic, gastrointestinal, central nervous system (CNS) or psychiatric disease, end-stage disease states, or any other disease that could interfere with the conduct or validity of the study or compromise participant safety.
- •Participant has a history of malignancy ≤ 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer (melanoma, leukemia, lymphoma and myeloproliferative disorders of any duration are excluded).
- •Participant has a history of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy.
- •Participant has reversible causes of atrial fibrillation (i.e.: cardiac surgery, pulmonary embolism, untreated hyperthyroidism).
- •Participant is to undergo pulmonary vein isolation or surgery for treatment of AF.
- •Participant had a severe, disabling stroke within the previous 6 months, any stroke within the previous 14 days, thromboembolism within previous 30 days or a transient ischemic attack (TIA) within 3 days prior to Visit
- •Participant requires renal replacement therapies (hemo- or peritoneal dialysis).
- •Participant has any of a list of defined laboratory abnormalities.
- •Prohibited Medications
- •Anti-platelet agents other than aspirin within 10 days prior to Visit 1 (excluding maintenance dose clopidogrel, prasugrel or ticlopidine) or fibrinolytic agents within 30 days prior to Visit
- •Aspirin greater than 162 mg/day.
- •Daily non-steroidal anti-inflammatory drug (NSAID) use.
- •Dronedarone, verapamil or ketoconazole.
- •Vitamin K antagonists (VKA) or other anticoagulants.
研究组 & 干预措施
Amiodarone
Experimental
Participants on betrixaban 30 mg and concomitant baseline amiodarone
干预措施: Amiodarone (Drug)
Amiodarone
Experimental
Participants on betrixaban 30 mg and concomitant baseline amiodarone
干预措施: Betrixaban 30 mg (Drug)
Betrixaban 60 mg
Experimental
Participants with lower weights
干预措施: Betrixaban 60 mg (Drug)
Betrixaban 90 mg
Experimental
Participants with higher weights
干预措施: Betrixaban 90 mg (Drug)
结局指标
主要结局
Steady-state C12 hr on Days 14, 18, and 21 After Weight-based Dosing
时间窗: Days 14, 18, and 21 of the PK period
Betrixaban PK concentration at 12 hr on Days 14, 18, and 21 in low and high weight groups
次要结局
- Steady-state C12 hr on Days 14, 18, and 21 After Weight and Amiodarone-based Dosing(Days 14, 18, and 21 of the PK period)
研究者
相似试验
已完成
2 期
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast CancerBreast CancerNCT06188559Eisai Inc.56
终止
1 期
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)Relapsed/Refractory Peripheral T-cell LymphomaNCT05403450Taiho Oncology, Inc.33
已完成
2 期
Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical CancerCervical AdenocarcinomaStage IB Cervical CancerStage II Cervical CancerStage III Cervical CancerNCT02880007Institut de Cancérologie de Lorraine48
已完成
1 期
Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014Advanced Solid MalignanciesNCT01026402AstraZeneca172
已完成
1 期
A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage TumorsAdvanced Solid NeoplasmsNCT02829099Janssen Research & Development, LLC95